Article Text

Download PDFPDF
Iatrogenic arsenic induced Mees’ lines
  1. A Bagic1,
  2. V Lupu2,
  3. C M Kessler3,
  4. C Tornatore4
  1. 1Department of Neurology and Neurosurgery, University of Pittsburgh Medical School, Pittsburgh, USA
  2. 2National Institutes of Health, Bethesda, USA
  3. 3Department of Internal Medicine, Georgetown University Hospital, Washington, USA
  4. 4Department of Neurology, Georgetown University Hospital
  1. Correspondence to:
 Dr V Lupu
 EMG Section, NINDS, NIH, Building 10, CRC, Room 7-5680, 10 Center Drive, MSC-1404, Bethesda, MD 20892-1404, USA; lupuv{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

A 43 year old white man, with acute myeloid leukaemia, resistant to induction (cytarabine + daunorubicin) and reinduction chemotherapy (cytarabine + daunorubicin + etoposide), accepted “a last resort” treatment with arsenic trioxide (0.15 mg/kg/day, intravenously; …

View Full Text